Suppr超能文献

局部应用瑞巴派特后持续性角膜糜烂的消退

Resolution of persistent corneal erosion after administration of topical rebamipide.

作者信息

Kashima Tomoyuki, Akiyama Hideo, Miura Fumihide, Kishi Shoji

机构信息

Department of Ophthalmology, Gunma University School of Medicine, Maebashi, Japan.

出版信息

Clin Ophthalmol. 2012;6:1403-6. doi: 10.2147/OPTH.S35122. Epub 2012 Aug 29.

Abstract

Rebamipide is an antiulcer agent used to treat gastric ulcer and gastritis. Biological effects of rebamipide include cytoprotection, wound healing, and anti-inflammatory properties that are known to be universal for a variety of tissues in addition to gastrointestinal mucosa. The therapeutic effects of rebamipide eye drops are due to its ability to increase corneal and conjunctival mucin-like substances and improve corneal and conjunctival injury in vivo. In this paper, we report a case of Sjögren's syndrome with complete disappearance of corneal erosion after administration of rebamipide eye drops. This was observed even though corneal erosion had not improved for 6 months after punctal occlusion surgery. The patient was a 33-year-old female, diagnosed with Sjögren's syndrome by a salivary gland biopsy. The corneal and conjunctival surfaces were filled with dense erosions, which did not improve with topical drugs. Punctal plugs were applied several times; however, the plugs were repeatedly shed. All four puncta of both eyelids were surgically occluded, and both corneal and conjunctival erosion was clearly improved. However, the erosion in the inferior cornea of both eyes had not improved for 6 months after surgery. We used the newly approved topical rebamipide for treatment of this patient. The corneal erosion gradually improved and completely disappeared 4 weeks after administration of the drug. Dry eye sensation disappeared at the same time. Both membrane-associated mucin and secreted mucin in the ocular surface are thought to be essential for maintenance of the tear film. Induction of mucin from ocular surface epithelium could be an effective treatment in cases of dry eye caused by mucin deficiency. Through its various mechanisms, rebamipide improves ocular surface conditions. To our knowledge, this is the first clinical case report using rebamipide ophthalmic solution. This drug may provide a novel approach to treat drying diseases of the eye.

摘要

瑞巴派特是一种用于治疗胃溃疡和胃炎的抗溃疡药物。瑞巴派特的生物学效应包括细胞保护、伤口愈合和抗炎特性,除了胃肠道黏膜外,这些效应在多种组织中都是普遍存在的。瑞巴派特滴眼液的治疗效果归因于其能够增加角膜和结膜的黏蛋白样物质,并在体内改善角膜和结膜损伤。在本文中,我们报告了一例干燥综合征患者,使用瑞巴派特滴眼液后角膜糜烂完全消失。即使在泪点闭塞手术后6个月角膜糜烂仍未改善的情况下,这种情况仍被观察到。该患者为一名33岁女性,经唾液腺活检诊断为干燥综合征。角膜和结膜表面布满密集的糜烂,局部用药后没有改善。多次应用泪点塞;然而,塞子反复脱落。双眼的所有四个泪点均通过手术闭塞,角膜和结膜糜烂均明显改善。然而,手术后6个月双眼下角膜的糜烂仍未改善。我们使用新批准的局部用瑞巴派特对该患者进行治疗。用药4周后角膜糜烂逐渐改善并完全消失。同时干眼症状消失。眼表的膜相关黏蛋白和分泌性黏蛋白都被认为对维持泪膜至关重要。从眼表上皮诱导黏蛋白可能是治疗黏蛋白缺乏引起的干眼病例的有效方法。通过其多种机制,瑞巴派特改善眼表状况。据我们所知,这是第一例使用瑞巴派特眼药水的临床病例报告。这种药物可能为治疗眼部干燥疾病提供一种新方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b922/3437954/df176c4184fb/opth-6-1403f1.jpg

相似文献

1
Resolution of persistent corneal erosion after administration of topical rebamipide.
Clin Ophthalmol. 2012;6:1403-6. doi: 10.2147/OPTH.S35122. Epub 2012 Aug 29.
2
Topical rebamipide improves lid wiper epitheliopathy.
Clin Ophthalmol. 2013;7:2137-41. doi: 10.2147/opth.s5451. Epub 2013 Oct 31.
3
Rebamipide ophthalmic suspension for the treatment of dry eye syndrome: a critical appraisal.
Clin Ophthalmol. 2014 May 30;8:1003-10. doi: 10.2147/OPTH.S40798. eCollection 2014.
4
Topical rebamipide improves the ocular surface in mild lagophthalmos.
Clin Ophthalmol. 2013;7:1333-8. doi: 10.2147/OPTH.S47445. Epub 2013 Jul 1.
5
Long-term rebamipide and diquafosol in two cases of immune-mediated dry eye.
Optom Vis Sci. 2015 Apr;92(4 Suppl 1):S25-32. doi: 10.1097/OPX.0000000000000523.
6
Persistent corneal epithelial defect responding to rebamipide ophthalmic solution in a patient with diabetes.
Int Med Case Rep J. 2016 May 10;9:113-6. doi: 10.2147/IMCRJ.S103299. eCollection 2016.
8

引用本文的文献

2
Transmembrane Mucin 1 Blocks Fluorescein Ingress to Corneal Epithelium.
Invest Ophthalmol Vis Sci. 2022 Feb 1;63(2):31. doi: 10.1167/iovs.63.2.31.
3
Diabetic keratopathy: Insights and challenges.
Surv Ophthalmol. 2020 Sep-Oct;65(5):513-529. doi: 10.1016/j.survophthal.2020.02.005. Epub 2020 Feb 22.
4
Persistent corneal epithelial defect responding to rebamipide ophthalmic solution in a patient with diabetes.
Int Med Case Rep J. 2016 May 10;9:113-6. doi: 10.2147/IMCRJ.S103299. eCollection 2016.
5
Long-term rebamipide and diquafosol in two cases of immune-mediated dry eye.
Optom Vis Sci. 2015 Apr;92(4 Suppl 1):S25-32. doi: 10.1097/OPX.0000000000000523.
6
Alkali burn treated with 2% rebamipide ophthalmic suspension: a case report.
Case Rep Ophthalmol. 2014 Nov 20;5(3):380-5. doi: 10.1159/000369201. eCollection 2014 Sep-Dec.
7
8
Rebamipide ophthalmic suspension for the treatment of dry eye syndrome: a critical appraisal.
Clin Ophthalmol. 2014 May 30;8:1003-10. doi: 10.2147/OPTH.S40798. eCollection 2014.
9
Topical rebamipide improves lid wiper epitheliopathy.
Clin Ophthalmol. 2013;7:2137-41. doi: 10.2147/opth.s5451. Epub 2013 Oct 31.
10
Topical rebamipide improves the ocular surface in mild lagophthalmos.
Clin Ophthalmol. 2013;7:1333-8. doi: 10.2147/OPTH.S47445. Epub 2013 Jul 1.

本文引用的文献

1
Rebamipide increases the mucin-like glycoprotein production in corneal epithelial cells.
J Ocul Pharmacol Ther. 2012 Jun;28(3):259-63. doi: 10.1089/jop.2011.0142. Epub 2012 Feb 15.
2
Effect of OPC-12759 on EGF receptor activation, p44/p42 MAPK activity, and secretion in conjunctival goblet cells.
Exp Eye Res. 2008 Apr;86(4):629-36. doi: 10.1016/j.exer.2008.01.007. Epub 2008 Jan 12.
4
Functions of MUC16 in corneal epithelial cells.
Invest Ophthalmol Vis Sci. 2007 Oct;48(10):4509-18. doi: 10.1167/iovs.07-0430.
6
OPC-12759 increases proliferation of cultured rat conjunctival goblet cells.
Cornea. 2006 Jun;25(5):573-81. doi: 10.1097/01.ico.0000208819.24990.0d.
7
15th anniversary of rebamipide: looking ahead to the new mechanisms and new applications.
Dig Dis Sci. 2005 Oct;50 Suppl 1:S3-S11. doi: 10.1007/s10620-005-2800-9.
9
Distribution of mucins at the ocular surface.
Exp Eye Res. 2004 Mar;78(3):379-88. doi: 10.1016/s0014-4835(03)00204-5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验